A randomized, double-blind, placebo-controlled, single dose, and multi dose incremental phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-201 in healthy adults
Latest Information Update: 06 Mar 2025
At a glance
- Drugs AC-201-Accropeutics (Primary)
- Indications Unspecified
- Focus Adverse reactions
Most Recent Events
- 06 Mar 2025 New trial record
- 08 Sep 2023 According to Accropeutics media release ,company announced that its oral small-molecule TYK2/JAK1 inhibitor AC-201 has been approved by the National Medical Products Administration (NMPA) to launch clinical phase 1 trial in China. AC-201 was approved for clinical trials by HREC in Australia in May 2023, and thePhase 1 clinical trial in Australia is currently underway.
- 12 May 2023 According to Accropeutics media release ,company announced that its oral small-molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch clinical phase I trial in Australia